Table 2 Asymptomatic versus symptomatic portal hypertensive biliopathy22.
| Asymptomatic | Symptomatic | p Value | |
|---|---|---|---|
| n (%) | 40 (75.5%) | 13 (24.5%) | — |
| Median (range) age (years) | 21 (13–34) | 35 (17–56) | <0.001 |
| Male: female | 29:11 | 7:6 | NS |
| Median (range) duration of EHPVO since diagnosis (years) | 4 (1–19) | 11 (1–23) | <0.022 |
| Median (range) duration of symptom (months) | — | 11 (0.5–96) | — |
| Gallstones | 0 (0%) | 7 (54%) | <0.001 |
| Median (range) bilirubin level (mg/dl) | 0.8 (0.4–3.9) | 2.7 (0.7–16) | <0.001 |
| Median (range) alkaline phosphatase level (IU/l)* | 94 (70–194) | 398 (97–1080) | <0.001 |
| ERC | |||
| Biliary stricture | 14 (35%) | 6 (46%) | NS |
| Biliary dilatation | 8 (20%) | 6 (46%) | 0.08 |
| Indentations | 20 (50%) | 5 (39%) | NS |
| CBD stones | 1 (2.5%) | 3 (23%) | 0.042 |
| Choledochal varices | 3 (7.5%) | 1 (7.7%) | NS |
CBD, common bile duct; EHPVO, extrahepatic portal venous obstruction; ERC, endoscopic retrograde cholangiography; NS, nonsignificant.
*Normal value, 70–140 IU/l.